---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038873"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:39:07.497308+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance

## Summary
- Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.
- Non-GAAP net income $10.7M ($0.24 EPS) vs $2.9M ($0.07) YoY; adjusted EBITDA $24.8M (+33%).
- On-X +24%, stent grafts +24%, BioGlue +4%, Preservation +3% constant currency growth.
- FY 2025 guidance raised: constant currency growth now 12-14%; reported revenue $435-443M.
- Retired $99.5M of convertible notes; FDA IDE approved for Arcevo LSA pivotal trial.

## SEC filing metadata
- accession: 0001628280-25-038873
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000162828025038873/0001628280-25-038873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000162828025038873/aort-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038873
- JSON: https://secwatch.observer/filing/0001628280-25-038873.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.